

Amendments to the Claims

1-53. (Cancelled)

54. (Currently amended) The ~~stent preform method~~ of claim [[52]] 64, wherein the therapeutic agent is disposed within pores of the outer sheath.

55. (Currently amended) The ~~stent preform method~~ of claim [[52]] 64, wherein the core is formed of shape-memory alloy.

56. (Currently amended) The ~~stent preform method~~ of claim [[52]] 64, wherein the outer sheath is formed of a polymeric material.

57. (Currently amended) The ~~stent preform method~~ of claim 56, wherein the polymeric material is biostable.

58. (Currently amended) The ~~stent preform method~~ of claim [[52]] 64, further comprising a release mechanism disposed over the outer sheath.

59. (Currently amended) The ~~stent preform method~~ of claim 58, wherein the release mechanism is a bioabsorbable polymer.

60. (Currently amended) The ~~stent preform method~~ of claim [[52]] 64, wherein the therapeutic agent is coated on the outer sheath.

61. (Currently amended) The ~~stent preform method~~ of claim 60, wherein a release mechanism is disposed over the therapeutic agent.

62. (Cancelled)

63. (Cancelled)

64. (Currently amended) A method of treating a vascular disease of a patient with ~~the stent preform of claim 52~~ a plurality of stent preforms interlaced to form a stent, the method comprising:

determining a prevalent disease process in the pathology of the vascular disease;

selecting the therapeutic agent to treat or prevent the prevalent disease process, ~~the plurality of [[the]] stent preforms including the therapeutic agent; and~~

implanting the stent preform in the patient to treat the vascular disease, ~~wherein each of the plurality of stent preforms comprises:~~

~~an elongated metallic core including a contact surface and first and second ends;~~

~~an outer sheath disposed about the contact surface of the core, the outer sheath including the therapeutic agent; and~~

~~caps disposed on the ends of the outer sheath thereby encapsulating the first and second end of the core.~~

65. (Cancelled)

66. (Cancelled)

67. (Previously presented) The method of claim 64, wherein the therapeutic agent is selected from the group consisting of cyclosporine A, imatinib mesylate, curcumin, and rapamycin.

68. (Previously presented) The method of claim 64, wherein selecting the therapeutic agent includes selecting two therapeutic agents.

Applicant(s): S. Jayaraman
Application No.: 10/696,174
Examiner: B. Pellegrino

69. (Previously presented) The stent preform of claim 68, wherein the two therapeutic agents are cyclosporine A and rapamycin, imatinib mesylate and rapamycin, or curcumin and rapamycin.